BR0209986A - Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias - Google Patents
Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratóriasInfo
- Publication number
- BR0209986A BR0209986A BR0209986-1A BR0209986A BR0209986A BR 0209986 A BR0209986 A BR 0209986A BR 0209986 A BR0209986 A BR 0209986A BR 0209986 A BR0209986 A BR 0209986A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- combination
- agonist
- anticholinergic agent
- obstructive airway
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"AGONISTA DE A2A EM COMBINAçãO COM UM AGENTE ANTICOLINéRGICO, PARA O TRATAMENTO DE DOENçAS OBSTRUTIVAS DAS VIAS RESPIRATóRIAS". A presente invenção refere-se a uma combinação de um agonista do receptor A~ 2a~ de adenosina seletivo e um agente anticolinérgico para administração simultânea, seq³encial ou separada pela via inalada no tratamento de uma doença obstrutiva das vias respiratórias ou outra doença inflamatória, com a condição de que o agente anticolinérgico nao seja um sal de tiotrópio.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29384201P | 2001-05-25 | 2001-05-25 | |
GB0129275A GB0129275D0 (en) | 2001-12-06 | 2001-12-06 | Pharmaceutical combination |
GB0210238A GB0210238D0 (en) | 2002-05-03 | 2002-05-03 | Pharmaceutical composition |
PCT/EP2002/005725 WO2002096462A1 (en) | 2001-05-25 | 2002-05-24 | An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209986A true BR0209986A (pt) | 2004-04-06 |
Family
ID=27256345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209986-1A BR0209986A (pt) | 2001-05-25 | 2002-05-24 | Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040171576A1 (pt) |
EP (1) | EP1395287A1 (pt) |
KR (1) | KR20030097901A (pt) |
CN (1) | CN1535161A (pt) |
AP (1) | AP2003002911A0 (pt) |
BG (1) | BG108383A (pt) |
BR (1) | BR0209986A (pt) |
CA (1) | CA2448086A1 (pt) |
CO (1) | CO5540324A2 (pt) |
CZ (1) | CZ20033126A3 (pt) |
EE (1) | EE200300586A (pt) |
HU (1) | HUP0400029A2 (pt) |
IL (1) | IL158774A0 (pt) |
MA (1) | MA27028A1 (pt) |
MX (1) | MXPA03010787A (pt) |
NO (1) | NO20035202D0 (pt) |
OA (1) | OA12609A (pt) |
PA (1) | PA8546101A1 (pt) |
PL (1) | PL366899A1 (pt) |
SK (1) | SK14302003A3 (pt) |
SV (1) | SV2003001055A (pt) |
WO (1) | WO2002096462A1 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
NZ545787A (en) | 2001-10-01 | 2007-12-21 | Univ Virginia | 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof |
GB0129273D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
SG155182A1 (en) | 2004-08-02 | 2009-09-30 | Univ Virginia | 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0511065D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
DE602007013441D1 (de) | 2006-09-29 | 2011-05-05 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EP2464649A1 (en) | 2009-08-12 | 2012-06-20 | Novartis AG | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
BR112014006223A8 (pt) | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン, エルエルシー | Mtor阻害剤を使用する強化された治療レジメン |
MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
DE69932173T2 (de) * | 1998-10-16 | 2007-06-06 | Pfizer Inc. | Adeninderivate |
GB9924363D0 (en) * | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
-
2002
- 2002-05-24 SK SK1430-2003A patent/SK14302003A3/sk not_active Application Discontinuation
- 2002-05-24 WO PCT/EP2002/005725 patent/WO2002096462A1/en not_active Application Discontinuation
- 2002-05-24 HU HU0400029A patent/HUP0400029A2/hu unknown
- 2002-05-24 US US10/479,085 patent/US20040171576A1/en not_active Abandoned
- 2002-05-24 MX MXPA03010787A patent/MXPA03010787A/es unknown
- 2002-05-24 IL IL15877402A patent/IL158774A0/xx unknown
- 2002-05-24 EE EEP200300586A patent/EE200300586A/xx unknown
- 2002-05-24 SV SV2002001055A patent/SV2003001055A/es not_active Application Discontinuation
- 2002-05-24 BR BR0209986-1A patent/BR0209986A/pt not_active IP Right Cessation
- 2002-05-24 KR KR10-2003-7015411A patent/KR20030097901A/ko not_active Application Discontinuation
- 2002-05-24 AP APAP/P/2003/002911A patent/AP2003002911A0/en unknown
- 2002-05-24 CN CNA028106180A patent/CN1535161A/zh active Pending
- 2002-05-24 PA PA20028546101A patent/PA8546101A1/es unknown
- 2002-05-24 PL PL02366899A patent/PL366899A1/xx unknown
- 2002-05-24 OA OA1200300303A patent/OA12609A/en unknown
- 2002-05-24 CA CA002448086A patent/CA2448086A1/en not_active Abandoned
- 2002-05-24 CZ CZ20033126A patent/CZ20033126A3/cs unknown
- 2002-05-24 EP EP02745316A patent/EP1395287A1/en not_active Withdrawn
-
2003
- 2003-11-18 CO CO03101662A patent/CO5540324A2/es not_active Application Discontinuation
- 2003-11-20 MA MA27409A patent/MA27028A1/fr unknown
- 2003-11-24 BG BG108383A patent/BG108383A/bg unknown
- 2003-11-24 NO NO20035202A patent/NO20035202D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL158774A0 (en) | 2004-05-12 |
AP2003002911A0 (en) | 2003-12-31 |
MA27028A1 (fr) | 2004-12-20 |
MXPA03010787A (es) | 2004-03-02 |
KR20030097901A (ko) | 2003-12-31 |
NO20035202D0 (no) | 2003-11-24 |
SK14302003A3 (sk) | 2004-08-03 |
CO5540324A2 (es) | 2005-07-29 |
CN1535161A (zh) | 2004-10-06 |
EE200300586A (et) | 2004-04-15 |
CZ20033126A3 (cs) | 2004-09-15 |
PA8546101A1 (es) | 2003-12-10 |
OA12609A (en) | 2006-06-09 |
WO2002096462A1 (en) | 2002-12-05 |
EP1395287A1 (en) | 2004-03-10 |
SV2003001055A (es) | 2003-11-14 |
HUP0400029A2 (hu) | 2004-04-28 |
PL366899A1 (en) | 2005-02-07 |
BG108383A (bg) | 2004-08-31 |
US20040171576A1 (en) | 2004-09-02 |
CA2448086A1 (en) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209986A (pt) | Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias | |
BR0209992A (pt) | Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias | |
BR0008039A (pt) | Combinações de formoterol e um sal de tiotrópio | |
BR0213397A (pt) | Método para suprimento de uma mistura de gases a um paciente, sistema para suprimento de gás a um paciente, usos de halotano, de enflurano, de isoflurano, de sevoflurano e de desflurano no sistema para suprimento, sistema para suprimento de medicamento, e, método para suprimento de medicamento terapêutico | |
CR9933A (es) | Agentes que se enlazan con un objetivo en el tejido pulmonar para el tratamiento de enfermedades respiratorias | |
BR0115910A (pt) | Compostos orgânicos | |
BRPI0514536A (pt) | uso de oligossacarìdeos não-digerìveis e sacarìdeo de galactose digerìvel, e, composição adequada para o tratamento e/ou prevenção de infecções do trato respiratório e/ou doença de infecção do trato respiratório | |
BR0008276A (pt) | Combinações de formoterol e propionato de fluticasona para asma | |
Bleecker et al. | The mechanism of rapid, shallow breathing after inhaling histamine aerosol in exercising dogs | |
Wilson et al. | Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice | |
WO2007002945A3 (en) | P2y6 receptor agonists for treating lung diseases | |
Brosnan et al. | Effects of hypercapnic hyperpnea on recovery from isoflurane or sevoflurane anesthesia in horses | |
BRPI0513953A (pt) | métodos para tratamento de doenças ou distúrbios mediados pela ccr2 | |
BRPI0712561B8 (pt) | Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida | |
BR0313503A (pt) | Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna | |
BR0214998A (pt) | Combinações farmacêuticas de agonistas do receptor da adenosina a-2a e do receptor adrenérgico beta-2 | |
BRPI0410374A (pt) | composição farmacêutica que compreende valsartano | |
BRPI0409387A (pt) | método para o tratamento de doença de tecido mole em um indivìduo mamìfero, composição farmacêutica, complexo de alvejamento de tecido mole, método para a formação de um complexo, e, kit para uso em um método | |
UY27308A1 (es) | Un agonista de a2a en combinación con un agente anticolinérgico para el tratamiento de enfermedades obstructivas de las vias aéreas | |
ECSP034863A (es) | Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas | |
Baumert | Xenon-based anesthesia: theory and practice | |
UY27565A1 (es) | Combinación farmacéutica. | |
Junor et al. | Lack of a role for cyclic nucleotide gated cation channels in lung liquid absorption in fetal sheep | |
BR0214776A (pt) | Combinação de um inibidor seletivo de pde4 e um agonista do receptor adrenérgico beta-2 | |
Díaz-Lobato et al. | High-flow nasal oxygen is not an oxygen therapy device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A , 5A , 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |